Experimental Liver-Directed therapy for eye cancer shows early promise but trial halted

NCT ID NCT04935229

Terminated Disease control Sponsor: TriSalus Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 26 times

Summary

This early-stage trial tested a drug called SD-101, given directly into the liver's blood supply, alone or with immune-boosting medicines, for people with a rare eye cancer (uveal melanoma) that spread to the liver. The study aimed to find a safe dose and check if the treatment could shrink tumors. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Columbia University Medical Center

New York, New York, 10032, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Stanford

Stanford, California, 94305, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
UCLA

Los Angeles, California, 90095, United States
University of Colorado

Denver, Colorado, 80045, United States
University of Miami

Miami, Florida, 33136, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
Washington University

Seattle, Washington, 98109, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC UVEAL MELANOMA IN THE LIVER